SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios latest earnings beat and raised full-year outlook were overshadowed by softer fourth-quarter organic-growth guidance, signaling a slowdown from the prior quarter. Traders are debating whether the selloff is an overreaction to the outlook or a justified repricing for decelerating growth and weaker customer expansion.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Investors are focused on Revolution Medicines upcoming quarterly update for the first full quarter of RASONQUE sales, especially whether new-patient starts show an accelerating launch ramp. Traders are weighing the drugs clinical success and broader pipeline against questions about commercial uptake, competition, and the stocks recent volatility.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is pulling back alongside weakness in cybersecurity and technology stocks, while traders also cite put-heavy options activity and circulate unverified claims of a DHS-related data exposure. The planned S&P 500 inclusion is a bullish counterpoint, but discussion questions whether index-related demand can offset sector pressure and valuation concerns.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradynes strong quarterly results are being overshadowed by a selloff as traders question its next-quarter outlook and cite margin pressure, product mix, and competition. Bulls point to AI-driven chip-testing demand, while bearish comments and put-heavy options positioning reflect concern that the growth outlook may not justify the stocks valuation.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rally and elevated trading activity have sparked bullish calls for a breakout, while traders debate whether it can clear resistance or will pull back. Supporters point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption will translate into value for the LINK token.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS and prompted a sharp selloff. Traders disagree over the threat, weighing Voceryqs potential to reduce surgeries against PAPZIMEOSs commercial head start and full-approval status, while questioning Inovios reimbursement and launch execution.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its relatively steady price action and repeated technical-trading discussion, with many posts describing consolidation or a pullback after a rally. Traders are split between viewing the dip as a healthy pause with long-term strength and worrying that TRX is lagging or could fall further.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is drawing attention after a sharp, high-volume selloff following a steep rally, with traders linking the move to profit-taking and a broader pullback across speculative genomics and biotech stocks rather than a clearly identified company-specific catalyst. The community is split between bearish concerns about valuation and insider selling and bullish claims of short pressure or market manipulation.

Onyxcoin (XCN) is a cryptocurrency launched in 2021and operates on the Ethereum platform. Onyxcoin has a current supply of 53,402,422,627.32441369 with 40,400,796,729.46127832 in circulation. The last known price of Onyxcoin is 0.00378971 USD and is down -1.54 over the last 24 hours. It is currently trading on 205 active market(s) with $5,616,621.35 traded over the last 24 hours. More information can be found at https://onyx.org.

Onyxcoin

Onyxs ecosystem expansionparticularly discussion of a Robinhood Chain testnet bridge involving ETH and tokenized TSLAis drawing attention, with some traders seeing potential in tokenized assets and payments. Others focus on XCNs weakness and volatile spikes, questioning whether the developments are translating into sustained demand.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP memecoins steep decline from its launch highs and reported losses among retail holders dominate discussion, with many traders calling it a pump-and-dump while others argue for accumulating or expect a rebound. The debate is closely tied to backlash over Trump and his familys crypto ventures, though claims of a deliberate scam remain traders opinions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MakeMyTrip (MMYT) Q2 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

MakeMyTrip Q2 2027 Earnings Call Transcript

MakeMyTrip (NASDAQ:MMYT) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

MakeMyTrip Q2 27 Earnings Conference Call At 7:30 AM ET

(RTTNews) - MakeMyTrip Ltd. (MMYT) will host a conference call at 7:30 AM ET on October 26, 2026, to discuss Q2 27 earnings results...

MakeMyTrip Limited to report Fiscal 2027 Second Quarter Financial & Operating Results on October 26, 2026

MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal 2027 second quarter financial and operating results before markets open on Monday, October 26, 2026. The company will post the release on its Investor Relations website at https://investors.makemytrip.com/ and will not distribute over...

Is It Worth Investing in MakeMyTrip (MMYT) Based on Wall Street's Bullish Views?

Based on the average brokerage recommendation (ABR), MakeMyTrip (MMYT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

MakeMyTrip Q1 2027 Earnings Call Transcript

On Monday, MakeMyTrip (NASDAQ:MMYT) discussed first-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

Is MakeMyTrip (MMYT) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in MakeMyTrip (MMYT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Industry Outlook GoDaddy, Vipshop, MakeMyTrip and QuinStreet 

GoDaddy, Vipshop, MakeMyTrip and QuinStreet have been highlighted in this Industry Outlook article.


4 Internet Delivery Services Stocks in Focus From a Flourishing Industry

The Zacks Internet - Delivery Services industry participants like GDDY, VIPS, MMYT and QNST are likely to benefit from increasing smartphone and Internet penetration.

Brokers Suggest Investing in MakeMyTrip (MMYT): Read This Before Placing a Bet

MakeMyTrip Ltd. engages in the provision of travel services. It offers air ticketing, hotels and packages, rail tickets, bus tickets, car hire, experiences and ancillary travel requirements such as foreign currency exchange services, visa processing, facilitating access to travel, and other insurance products. The company was founded by Deep Kalra and Rajesh Magow on April 28, 2000 and is headquartered in Gurgaon, India.

MakeMyTrip Ltd

Why Did MakeMyTrip Stock Fall Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Citi cut MakeMyTrip’s price target to $96 from $108, while maintaining a ‘Buy’ rating on the shares after its earnings results.&nbsp;</li><li>Morgan Stanley lowered its price target on the company to $106 from $113 while maintaining an ‘Overweight’ rating on the shares.&nbsp;</li><li>The company missed revenue estimates, reporting quarterly revenue of $295.7 billion, compared to analyst expectations of $310 billion, as per Fiscal.ai data.</li></ul><p>Shares of online travel company MakeMyTrip Ltd. (MMYT) fell over 12% on Wednesday after the company received target price cuts from Morgan Stanley and Citi following its third-quarter (Q3) 2026 results.</p><p>Citi cut MakeMyTrip’s price target to $96 from $108, while maintaining a ‘Buy’ rating on the shares after its earnings results.</p><p>Meanwhile, Morgan Stanley lowered its price target on MakeMyTrip to $106 from $113 while maintaining an ‘Overweight’ rating on the shares.</p><h2 class="st-heading-2">Earnings Results</h2><p>The company missed revenue estimates, reporting quarterly revenue of $295.7 billion, compared to analyst expectations of $310 billion, as per Fiscal.ai data.</p><p>However, MakeMyTrip beat analyst expectations on earnings per share, reporting $0.07 EPS for the quarter, versus an expectation of $0.01.</p><p>For the quarter, the company’s adjusted net profit grew to $51.4 million versus $44.9 million in the same period last year, an improvement of $6.5 million. The company also reported a 11.8% increase in gross bookings. The company’s profit for the quarter decreased almost 73% year-on-year to $7.3 million in Q3 26, compared to $27.1 million in Q3 25.</p><h2 class="st-heading-2">Street Consensus</h2><p>Morgan Stanley said it lowered its price target on MakeMyTrip after the company's latest earnings report. The analyst said it lowered its estimates to moderate the expected pace of margin expansion for FY27 and FY28, according to TheFly.</p><p>Meanwhile, Citi said that it views MakeMyTrip’s growth as solid amid "challenging circumstances," according to TheFly. However, the analyst lowered its estimates after the company’s earnings, factoring in more modest margin assumptions.</p><p>Citi, however, said that it views MakeMyTrip's valuation as attractive at current share levels.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MMYT">MMYT shares</a> remained in the ‘neutral’ territory over the past 24 hours amid ‘high’ message volumes.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_22_at_3_19_19_AM_png_0d39fc48a4.webp" alt="On Stocktwits, retail sentiment around MMYT shares remained in the ‘neutral’ territory over the past 24 hours amid ‘high’ message volumes." width="1274" height="153"></figure><p>Shares of MMYT lost over 34% in the past year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

People travel through Hartsfield-Jackson Atlanta International Airport on November 7, 2025 in Atlanta, Georgia. (Photo by Megan Varner/Getty Images)

MakeMyTrip Ltd. received target price cuts from Morgan Stanley and Citi following its third-quarter results that were below market expectations. 

Amplify Travel Tech ETF

Exchange Traded Concepts Trust - ETCT EMQQ The Emerging Markets Internet and Ecommerce ETF

SPDR Portfolio Emerging Markets ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$42.68
Prev Close	$43.00
Open	$43.06
Dividend Yield	0.00%
50-Day Moving Average	$48.73
Beta	1.36
Avg. Volume	864,240.55
PE Ratio	99.46

52-Week High	$86.94
52-Week Low	$32.67
Market Capitalization	$4.01B
EPS (Annual)	$0.508
Price to Book	-11.05
Revenue Per Employee	$189,575.27

Feed

News

Sentiment

Earnings

Fundamentals

Info

MMYT Fundamentals